Regencell Bioscience Holdings Ltd

NASDAQ RGC

Download Data

Regencell Bioscience Holdings Ltd Working Capital to Current Liabilities Ratio 5 year CAGR for the quarter ending September 30, 2023: 297.78%

Regencell Bioscience Holdings Ltd Working Capital to Current Liabilities Ratio 5 year CAGR is 297.78% for the quarter ending September 30, 2023. The working capital to current liabilities ratio measures the proportion of working capital to current liabilities. It is calculated by dividing the difference between current assets and current liabilities by current liabilities. This ratio indicates the company's ability to cover its current liabilities with its working capital. A higher ratio suggests a healthier liquidity position and better ability to meet short-term obligations. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Regencell Bioscience Holdings Ltd Working Capital to Current Liabilities Ratio for the quarter ending June 30, 2021 was -0.98.
  • Regencell Bioscience Holdings Ltd Working Capital to Current Liabilities Ratio for the quarter ending June 30, 2017 was -0.11.
NASDAQ: RGC

Regencell Bioscience Holdings Ltd

CEO Mr. Yat-Gai Au
IPO Date July 16, 2021
Location Hong Kong
Headquarters First Commercial Building, Causeway Bay, Hong Kong
Employees 12
Sector Healthcare
Industry Drug manufacturers - specialty & generic
Description

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder, as well as infectious diseases. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Similar companies

EGRX

Eagle Pharmaceuticals Inc

NA

NA

PAHC

Phibro Animal Health Corporation

NA

NA

PROC

Procaps Group SA

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email